Clinical Trial Update: Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) [Phase 2]

View source ↗

Summary

Phase 2 trial update of ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nodular Lymphocyte-predominant Hodgkin Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: University of Cologne | Conditions: Nodular Lymphocyte-Predominant Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED